Stockreport

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones [Yahoo! Finance]

Annexon, Inc. - common stock  (ANNX) 
PDF Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; [Read more]